endothelial dysfunction Market

The global endothelial dysfunction market size was valued at US$ 1,995.17 million in 2022 and is expected to reach a value of US$ 2,584.84 million by 2028; the market is estimated to record a CAGR of 4.4% from 2022 to 2028.

The market growth is attributed to increasing incidence of cardiovascular diseases and rising incidence of high cholesterol, diabetes, and obesity.

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide. According to the Centers for Disease Control and Prevention (CDC), over 60 million women (44%) in the US suffer from some form of heart disease. Heart disease is the leading cause of death among women in the US and can affect women of any age. In 2021, it caused 310,661 deaths among women, i.e., nearly one in five female deaths. According to an article entitled "Young Indians Are at Higher Risk of Coronary Artery Disease," by Dr. O. Yadava, C.E.O. & Chief Cardiac Surgeon, National Heart Institute, New Delhi, current scientific evidence shows alarming results; CAD rates among Indians are staggering 50-400% higher than any other ethnic group. The prevalence of CAD in the West has fallen by half over the past three decades. However, the rates in India have doubled, and there is no sign of a decline.

According to the American Heart Association, almost half of all adults in the US suffer from a type of CVD. Over 130 million people, i.e., 45.1% of the US population, are projected to suffer from a type of CVD by 2035. According to reports by the European Society of Cardiology, CVDs cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU). In short, they account for 45% of all deaths in Europe. Over the past 25 years, the absolute number of CVD cases and new CVD cases have increased in Europe. There is a high prevalence of cardiovascular risk factors in Central and Western Europe owing to smoking habits and heavy drinking rates among men. More than 4 million Europeans die yearly from cardiovascular diseases mainly due to coronary artery disease (CHD) and stroke. As per the report "Beyond the Burden: The Impact of Atrial Fibrillation in Asia Pacific," by Biosense Webster, published in 2019, more than 16 million people in Asia Pacific suffer from atrial fibrillation, which is expected to reach ~72 million by 2050. The report also suggests that the middle-aged and elderly population is more prone to develop this condition.

According to the World Heart Federation, cardiovascular disease is the primary cause of death in the Middle East & North Africa, accounting for more than a third of all deaths or 1.4 million people annually. Further, CVD deaths have increased by 48% over the past 30 years, which accounted for 40% and 10% of deaths in Oman and Somalia, respectively. In 2021, age-standardized CVD mortality rates in the Middle East & North Africa ranged from 134.2 to 600.2 per 100,000 people.

Therefore, the high prevalence of cardiovascular diseases is likely to drive the endothelial dysfunction market growth.

Product-Based Insights

The endothelial dysfunction market, based on cause, is segmented into hypertension, diabetes, hypercholestrolaemia, Bechet's disease, obesity, and others. The hypertension segment held the largest share of the market in 2022. However, diabetes segment is anticipated to register the highest CAGR of 4.6% in the market during 2022-2028. Cardiovascular complications are the results of chronic vascular complications caused by diabetes. Many research articles have shown links between insulin resistance and endothelial dysfunction. However, it is still not understood how diabetes affects endothelium. Diabetes is directly related to risks of microvascular pathologies, such as atherosclerotic diseases, retinopathy, nephropathy, and neuropathy. Thus, the risk of cardiovascular disease increases exponentially in patients suffering from diabetes. According to the research article 'Endothelial Dysfunction in Diabetes,' published in May 2020 by MDPI journals, patients with prediabetic conditions, such as impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), also show accumulating evidence that implicates endothelial dysfunction as an event. Considering the above-listed factors, the demand for endothelial dysfunction treatment is estimated to increase exponentially.

Cause-Based Insights

Based on cause, the endothelial dysfunction market is segmented into hypertension, diabetes, hypercholestrolaemia, Bechet's disease, obesity, and others. Hypertension was the largest endothelial dysfunction market share holder in 2022. The diabetes segment is anticipated to register the highest CAGR from 2022 to 2028.

End User-Based Insights

Based on end user, the endothelial dysfunction market is categorized into hospitals, diagnostic centers, clinics, and others. Hospitals was the largest market share holder in 2022 and is anticipated to register the highest CAGR from 2022 to 2028.

Further, the number of people with diabetes is growing widely worldwide. According to the International Diabetes Federation (IDF), by 2045, the number of people with diabetes will rise to 600 million from 425 million in 2020. Thus, the growing number of diabetic people drives the endothelial dysfunction market growth for the diabetes segment.